AMYT.L Regulatory News (AMYT)

10 January 2018

AIM: AMYT

ESM: AYP

Amryt Pharma plc

("Amryt" or the "Company")

New Distribution Agreement Signed

Expanding Route to Market

Amryt, a biopharmaceutical company focused on rare and orphan diseases, is pleased to announce that it has further expanded its route to market for Lojuxta® (lomitapide), having signed an exclusive distribution agreement covering Central and Eastern Europe ("CEE") with GryNumber Health ("GryNumber"). GryNumber is one of the leading healthcare consultancy and distribution companies in the region, with many years of experience.

The agreement covers the distribution of Lojuxta across Austria, Croatia, Czech Republic, Estonia, Finland, Hungary, Latvia, Lithuania, Poland, Slovakia and Slovenia. Lojuxta is a treatment for the rare, life-threatening, genetic cholesterol disorder Homozygous Familial Hypercholesterolemia ("HoFH") and Amryt estimates that there are approximately 100 patients with HoFH in these countries, with requests for access to Lojuxta made by clinicians throughout the region.

Amryt has signed distribution contracts covering Saudi Arabia and Switzerland recently as it continues to develop sales of Lojuxta, having acquired exclusive marketing rights to the drug across certain territories in December 2016.

Dr. Joe Wiley, Chief Executive Officer of Amryt Pharma, said:

"GryNumber Health has a well-established presence in, and significant experience of, the healthcare markets in Central and Eastern Europe and therefore is an ideal partner for us in the region. We are delighted to have signed this exclusive distribution agreement as we look to provide access to Lojuxta to patients suffering from HoFH across our licensed territories."

Enquiries:

About Amryt Pharma plc

(www.amrytpharma.com)

Amryt Pharma is a specialty biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.

The Company holds an exclusive licence to sell Lojuxta (lomitapide) for adults, across the European Economic Area, Middle East and North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body's ability to remove LDL cholesterol ("bad" cholesterol) from the blood. This typically results in extremely high blood LDL cholesterol levels, leading to aggressive and premature narrowing and blocking of arterial blood vessels. If left untreated, heart attack or sudden death may occur in childhood or early adulthood.

Amryt's lead drug candidate, AP101, is a potential treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. It is currently in Phase 3 clinical trials. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion.

Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease. 

The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.

About GryNumber Health

(www.grynumberhealth.com)

GryNumber Health is a healthcare consultancy and distribution company dedicated to helping businesses become more effective and successful while increasing their competitive edge in today's constantly evolving market. While specialising in providing access to small and medium size markets in Europe for Pharmaceutical and Diagnostic companies, GryNumber Health creates new opportunities for patients, healthcare professionals and businesses.